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Summary
In highly developed nations, valve surgery will be increasing applied in older people, with more co-morbidities and a higher incidence of
concomitant coronary artery disease. Valve surgeons will be facing increased competition from the catheter-based procedures, both for valve
repair and replacement; these are already applied clinically, and their numbers will rise in near future. Early mortality in double valve
procedures and in combined CABG and valve operations remains substantial, and there is ample room for improvement of surgical results. New
valve prostheses are slow in development, due to financial restraints and exceeding cost of certification. Tissue-engineered valves are being
developed, but are not ready for larger clinical trials. Cardiac surgery is undergoing a rapid transformation; radical changes both in scope and
workload of cardiosurgical units in Europe can be expected in near future. Socio-economic factors and recent advances in medical technology
contribute to these changes.
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In the second half of the 20th century, an unprecedented
prolongation of human life has been observed. Average life
expectancy in the countries of the European Union (EU) rose
almost 9 years from1960 to2000 (Fig. 1), and the increase was
most marked in less developed EU countries. The surgeons
will be treating an increased number of aged people; US
expects that the aged population (O65 years) will double by
2040 (Fig. 2); by that time it will reach 77 million, more than a
quarter of total US population. Cardiosurgical consequences
are obvious: degenerative heart disease (aortic stenosis,
mitral regurgitation, heart failure, total AV block) will be
encountered more frequently than before, and surgery will
assume exceedingly complex proportion in this population
with multifocal atherosclerosis. This fact is well reflected in
the recent European Survey by Bruce Keogh [1], where the
major increase has been observed in the segment of
combined CABG and valve procedures.2. Reduced incidence of coronary heart disease
This trend has been observed in highly developed nations
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This development is already reflected in reduction of
coronary artery bypass grafting (CABG) procedures, which
has been observed in recent years in highly developed
nations, and will greatly change the scope and amount of
work in cardiosurgical units.3. Rapid development of invasive cardiology
In highly developed nations of Europe and North America,
catheter interventions greatly outnumber the operative
treatment of coronary atherosclerosis (Figs. 4 and 5), and
STS database shows a 23% reduction of CABGs in recent
years.1 The growth of invasive cardiology does not remain
limited to PTCA and stenting of the coronary arteries.
Percutaneous balloon mitral valvotomy is already estab-
lished as a primary treatment of mitral stenosis [2], although
the same technique is very unsatisfactory in the treatment
of aortic stenosis. Percutaneous, catheter-based treatments
of mitral insufficiency, both by edge–edge repair and
reduction of posterior leaflet of the mitral valve via coronary
sinus [3], are being explored, and one can assume that theseEuropean Journal of Cardio-thoracic Surgery 26 (2004) S8–S13www.elsevier.com/locate/ejcts1 http://www.ctsnet.org/file/STSNationalDatabaseSpring2004AdultCar-
diacExecutiveSummary.pdf Table 1.
Fig. 1. Life expectancy for men and women, EU 15, 1960–2000.
Fig. 2. Elderly population.
Fig. 4. CABG procedures in USA STS database, 1993–June 2002.
Fig. 5. Decrease of CABG procedures in UK.
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larger clinical trials in near future. Pulmonary valve
replacement by catheter technique is already established
in pediatric population [4], and percutaneous aortic valveFig. 3. Decrease of cardiovascular mortality in males.replacement is being developed [5]. In spite of many
setbacks, this development will continue, and cardiac
surgeons can expect to lose a substantial part of their
established field of valvular surgery, which will be taken over
by invasive cardiologists. It is obvious that the surgeons,
being unable to stop or block such a development, will have
to adopt these techniques, both to assure the safety of new
interventions, and to able to perform them together with
catheter interventionists.4. Expected changes in the field of valve surgery
In terms of operative techniques, only few changes have
occurred in the last decade. Myocardial protection has been
considerably improved, although the mortality of valvular
procedures remains higher than in CABG, especially in
combined procedures (CABG and valve) and in double valve
operations (Table 1), as also shown in STS database.2 Major
breakthrough is hardly to be expected in this particular area,
both due to the increasing age of patient population, and to
the diffuse atherosclerotic disease in coronary system and in
the aorta. Patients rarely succumb to the operation itself:
primary myocardial failure after surgery (‘postoperative low
output syndrome’) can be controlled by drugs and by
temporary heart assist devices (primarily IABP). Neurological
mortality is assuming increasing proportion, especially in2 http://www.ctsnet.org/file/STSNationalDatabaseSpring2004AdultCar-
diacExecutiveSummary.pdf Fig. 8.
Table 1
In complex valvular procedures, there is ample room for improvement in surgical results
Without CABG With CABG
Initial Repeat Initial Repeat
No. Died % No. Died % No. Died % No. Died %
Double valves
Mitral and aortic 326 29 8.9 60 4 6.7 122 20 16.4 11 3 27.3
Mitral and tricuspid 55 6 10.9 26 7 26.9 16 5 31.3 0 0 0.0
Aortic and tricuspid 5 1 20.0 4 1 25.0 1 0 0.0 0 0 0.0
Other double valves 4 1 25.0 0 0 0 0 0.0 0 0 0.0
Double total 390 37 9.5 90 12 13.3 139 25 18.0 11 3 27.3
UKCSR: multiple open valve operations financial year ending 2001.
Table 2
Role of homografts is grossly overrated (1.6%)!
Without CABG
Initial Repeat
No. Died % No. Died %
Aortic
Valvotomy/repair 17 0 0.0 0 0 0.0
Mechanical valve 1474 30 2.0 166 4 2.4
Bioprosthesis 1480 65 4.4 85 8 9.4
Homograft 48 0 0.0 25 1 4.0
Autograft 24 0 0.0 2 0 0.0
Aortic total 3043 95 3.1 278 13 4.7
For comparison: in Germany 0.7%; UKCSR: single open valve operations financial year ending 2001.
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morbidity and mortality of this complication are very
high [6].
Development of valve prosthesis has been stagnant in the
recent years, and no major breakthroughs are presently
visible. Durable mechanical valves still need anticoagulation
and are prone to thrombosis and embolism; a truly
antithrombogenic mechanical valve has not been yet
developed, in spite of the remarkable progress in heparin
bonding. Biological valves are still not durable, and are only
of limited use in younger population. Presently, they are
used in exceeding numbers, due to the aging of the
population being subjected to valve replacement. Recent
statistics [7] show that in UK almost half of patients with
aortic valve replacement receive biological valves. Homo-
grafts—due to the difficulties in obtaining good valves—play a
minimal role, and their numbers are not expected to rise in
the future (Table 2).
Valve repair plays a major role in mitral surgery, and the
proportion of patients with this procedure is expected toTable 3
Mitral repair is not always possible (UKCSR 35%)!
Mitral
Valvotomy/repair 502 9 1.8
Mechanical valve 774 39 5.0
Bioprosthesis 145 14 9.7
Homograft 0 0 0.0
Other 1 1 100.0
Mitral total 1422 63 4.4
For comparison: in Germany 43%.rise, with surgeons gaining experience with various methods
of valve repair (Table 3). In aortic surgery, various methods
of aortic valve repair in the dilated aortic root are gaining
acceptance, but the absolute numbers will probably remain
low, due to the rarity of the condition (normal, tricuspid
aortic valve with isolated dilatation of sinus portion of the
ascending aorta). Ross procedure is very popular in children
and young adults, but the absolute numbers remain low, due
to the relative complexity of the surgical correction and
necessity to implant another prosthesis in pulmonary
position, with uncertain long-term results (Table 2).
Tissue engineering has played a major role in the
development of autologous-cell, bench engineered valve
prosthesis. Numerous publications have addressed this
problem, and many animal studies have demonstrated the
possibility to construct a non-thrombogenic valve prosthesis
from autologous or homologous cells, derived from various
sources [8,9]. Nevertheless, lasting function has been
demonstrated only in the low-pressure circulation, and
human implants have been rare. This field is expected to25 5 20.0 255
218 24 11.0 318
41 9 22.0 108
0 0 0.0 0
0 0 0.0 1
284 38 13.4 682
M.I. Turina / European Journal of Cardio-thoracic Surgery 26 (2004) S8–S13 S11grow in future, although technical problems remain sub-
stantial. A major capital investment will be necessary to
provide cardiac surgeons with a workable tissue-engineered
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Appendix. Conference discussion
Dr J. Pomar (Barcelona, Spain): As you mentioned at the end,
thromboembolism is one of the limitations. Do you think the new
antithrombotic drugs may help or may change or modify the future? There
is a few now coming, like ximelagatran, for instance, which has not been used
as anticoagulation treatment for valve replacement, but it seems to be easier
to control and have less side effects than older drugs like coumadin or so. Do
you think it is going to make an important difference or not?
Dr Turina: I think they are going to make an important progress in the
treatment, especially the platelet inhibitors, which are now being analyzed in a
much more effective fashion. There are huge differences in individual
responses among the patients, and present approach with everybody receiving
100 aspirin or 75 mg of Plavix is a gross oversimplification. The problem of
resistance to anticoagulation will be an important one, but still I do not see in
near future a mechanical valve which will need no anticoagulation.
Dr Pomar: Axel (Axel Haverich), maybe you have some input on the
different use of getting the INR in Germany today at home, not in the hospital,
as we have been using for years, and also about some particular valves having
only antiplatelets.
Dr A. Haverich (Hannover, Germany): There was a trial that was
discontinued last week with one mechanical valve. Patients were put on
aspirin only. Because of one fatality, the trial was discontinued.
In the area of mechanical valves, I don’t see that we are finding much
progress. Yesterday I heard that even with ximelagatran and newer drugs that
the bleeding complications may actually be similar to what we see in the
coumadin treatment.
But for a meeting like this, I am sorry to say, and your time for preparation
was very short, Marko (Marko Turina) but the flavor of this presentation should
be different. We should not talk about the problems that we have with the
current design that we have been talking about for the last 20 years and sayingthat the homografts play such an important role. The flavor of these talks,
looking to the future should be not that tissue engineered grafts would be
available only in the far future. There have been attempts of using tissue
engineered valves in the last five years. There are the first valves coming out
now clinically, like the Konertz group in Berlin, who has done nearly 150
implants, in the pulmonary position, of course.
And I think we should not say, well, these are the problems and the
mortality is high. I think the flavor should be, we have these problems and we
have to look that the mortality comes down and this would be the strategy to
get this done, number one. This is how we not only improve survival, operative
and long-term, but we also improve quality of life for the patient. We must
talk about pediatric use, that we have valves that would grow with the patient
and see with a more optimistic fashion into new developments. I see tissue
engineered valves as a potential huge progress.
I would like to make a comment about the mortality in the present and in
the future. In response to your question about the operative mortality being
higher, we must address the septum, since it is a key link to survival because
the right heart failure that develop may be fatal. Until now we have accepted
the concept that the postoperative septum that is akinetic or hypokinetic
postoperatively is a commonplace phenomena. This is wrong because I believe
this complication is related to stunning that results from inadequate
protection. We must then study the septum before and after the procedure
to determine if the septum is working or not working. If it is not working
postoperatively, yet worked preoperatively, this indicates the septum
sustained intraoperative damage. Management of this complication means
that your techniques of protection must be changed to allow the septum work
normally. A good way to evaluate this process in your center is to review your
results after OPCAB procedures where your cardioplegia methods are not
used, and the septum works every time. This avoidance of damage occurs
because you have not injured this structure. We use the integrated
cardioplegic technique to avoid damage and do not see septal injury.
However, the barometer of success is presence or absence of septal damage.
Therefore it does not matter which cardioplegic technique is used so long as
septal injury is avoided. If your method causes damage, it should be changed.
The positive consequence of this change will be that right heart failure will
not occur.
Now let us assume that we solve the intraoperative problem in each
instance, and thus assure 100% hospital survival following replacement of one
valve or two valves. We must then look at long-term mortality, and
longitudinal studies show very clear findings that are discouraging. Analysis
of late results in patients with aortic or mitral insufficiency that present with
!40% ejection fraction, and large ventricular size shows only 30% 10 year
survival. This means that 70% of these patients will be dead in 10 years,
regardless of how perfectly the valve replacement or repair corrects the
insufficiency, and despite complete absence or operative mortality. The
underlying reason is that we have only addressed the valve and did not address
the ventricle. These patients succumb because of the complications of heart
failure, which is the major health hazard that Friedhelm Beyersdorf talked
about in his introduction. They develop chronic CHF or arrhythmic death, and
our potential management change is to begin to look at how we change
ventricular form at the time we correct the underlying valve problem. The
geometric problem that follows valve insufficiency is the development of a
spherical ventricle. This abnormal dilated chamber dimension is similar to the
spherical ventricle that happens with ischemic heart failure. The difference
with valvular cardiomyopathy is that all the muscles are alive; but the form is
abnormal and we must consider how to fix this problem
My belief is that the future requires that we must deal with both the valve
and the ventricle. As this new vantage point develops, a whole new look will
emerge at what we do intraoperatively, so that the cardiac surgery arena will
change as we begin to treat another target—the ventricle.
Dr T. Wahlers (Jena, Germany): Another point I think we should think
about life quality after valve surgery in the older age group. With regard to the
mortality we observe, I think we have to provide figures that life quality in a
90-year-old man, for example, is good even if he lives longer only two to three
to four years.
We need competitive data for the cardiologists facing the new interven-
tional procedures coming up to advocate that cardiac surgery in these old
patients is worth the effort and money spent.
There are no clear figures available. We have these unclear survival figures
from the literature. You now showed clear figures from the UK registry, which
are much better, but there are no long-term figures available in order to say it
is good to operate on a 90-year-old. The only argument we are always giving is
that our personal mortality is low in these type of patients.
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addressing the problem of the quality of life after surgery, and it is surprising
that there is a substantial group of patients, especially in coronary surgery,
where the quality of life does not improve after operation, or even
deteriorates. It is basically the brain complications of procedures, both
coronary and valves, which make the patient suffer.
Dr J. Vaage (Oslo, Norway): We are talking about two different directions
here in valve surgery: it is tissue engineered valves or the percutaneous repair
or implantation. Even if a tissue engineered valve is very, very good, you still
have the surgery, and if we look at the progress in endovascular procedures, I
think it is quite logical that we will during the next 10 years look into a large
improvement in this and how this can also be done with valves. And society
and patients, they always want a percutaneous procedure. If surgeons still
want to implant valves in the future, they also have to go to the cath lab and
start training also in the cath lab.
Mr R. Guezuraga (Minneapolis, MN, USA): I am Bob Guezuraga from
Medtronic, and I am the nonsurgeon that is here, so I look at this from a
business perspective.
With respect to mechanical valves, there isn’t a lot of investment going on
in this area. I would say that the last valve that was approved here in Europe
and yet to be approved in the United States is the valve that Medtronic
designed. When I approved that project within Medtronic, it wasn’t because I
thought there was a tremendous future growth for mechanical valves, it was
to fill out a basket of product offerings. The future within the valve business,
where I do see the growth, where the investments are being made, is on the
biological side and also tissue engineered.
But this whole concept of percutaneous repair and then hopefully one day
the delivery of an aortic valve through a percutaneous technique is going to be
a reality, because the investment dollars are going there. The research
institutions, the companies that are in the business today that are putting $30
and $40 million dollars a year into R&D are putting the money in those areas,
and those are budgets that are much higher than I am sure most of the
universities have in their smaller labs, important labs nonetheless, that is the
direction that I see it going.
We are talking about having to use drugs associated to mechanical valves,
and if we can get the durability and the performance of the biological valves,
then we have the best of all worlds, and that is where I see the future going.
The concept of percutaneous is something that we are going to have to
learn how to deal with: how do we get that valve there, how do we place it,
what do we do with the native valve that is already in that position?
Dr O. Alfieri (Milan, Italy): To have better long-term results you have to
operate on patients early in the course of the disease, before left ventricular
dysfunction occurs; but cardiologists are generally against this because of the
complications related to the artificial valves. I wonder whether it could be
useful to stratify patients to know the valve-related complications according
to the stage of the disease.
Dr Turina: I am still observing that mortality after valve surgery varies
very much among different countries in Europe. In Switzerland patients are
referred for aortic valve replacement much earlier, because the cardiologists
have learned that left ventricular function in many patients does not improve
after valve replacement, due to the variable amount of myocardial fibrosis.
We are advocating surgery at the first signs of deterioration in the left
ventricular function, when the wall thickness or left atrial size increase, or at
the first onset of atrial fibrillation. So I think the indication for valve surgery is
changing, but you must keep the mortality of primary aortic valve procedure
below 1%, and in the mitral valve repair at less than 0.5%.
Dr Alfieri: Certainly in those cases the valve-related complication rate is
much lower, but this has not been clearly proved. A potential increase of
candidates for valve surgery can be seen.
Dr Turina: I can tell you an interesting observation. Ludwig von Segesser
and myself have been looking for patients who would be candidates for the
Batista procedure. I never see a good patient for a Batista procedure; I never
see a failing left ventricle with a length diameter of more than 10 cm, because
they are treated so well with various drug combinations that this deterioration
simply does not occur. So the differences in valve surgery mortalities in
Europe, are at least in part determined by the timing of surgery.
Dr F. Beyersdorf (Freiburg, Germany): I would like to make two
comments. First, what you just said with the percutaneous implantation of
valves, I think that we have to have in our ORs the equipment for doing X-ray.
Very seldom we have it today. And the next step will be that the new MR
techniques will allow us maybe to even operate in the MR setting, because it is
a half open one, and in Zurich I think you have already one where it is half openand tiny slim people can stand there doing some sort of surgery in the chest
somewhere. So I think this will be the next development, and if you look to the
X-ray companies and the imaging companies, they are producing machines
where in the future you might be able to do surgery using this kind of
visualization technique.
Second, you said that the mortality in valve surgery is relatively high, which
is correct. One of the reasons I think is that we are treating 90-year-old
patients, and even though the heart is fine after the operation, they are still 90
years old. They have COPD, renal disease, etc. We need more exchange with
our other colleagues, who care for the patient pre-, intra- and postoperatively.
Dr C. Mestres (Barcelona, Spain): I totally agree with Friedhelm
Beyersdorf. I think it is a fundamental point. So we should not send anybody
to the cath lab. We must create our cath lab. I think there are some
experiences. We still do this thing, this wire still, this is myself, keep doing
peripheral angioplasties just to keep this thing alive. And so the department
should be responsible for that. When everything goes for simplicity, we must
recall that.
I remember in the city of Frankfurt coming to visit a fellow eight years ago
in a small clinic, at Hoechst Clinic here, called Wolf Stelter, who was very
famous because he was one of the pioneers in abdominal aortic repairing
through an endovascular prosthesis. He was a general surgeon assisted by an
orthopedic surgeon in the operating room, so far away from what is very
complicated today. So I think we must build our cath lab by doing whatever
thing in the operating room. I think it is a fundamental issue for the future.
This is why I totally agree with Friedhelm. So we must lead this move.
Dr G. Gerosa (Padova, Italy): I would like to take advantage of the
comments of the last discussants. I appreciated what you said, where is the
future? I believe that the lesson learned from the past from the stent business,
the future is where the money is going to be put for future developments and
for research technologies. So the future would be for endovascular
implantation prostheses.
Regarding timing of surgery, yes, there is something wrong with timing of
surgery with some valve disease, but the timing for a percutaneous procedure
ruled by the cardiologists will be totally different. So definitely we are going to
treat advanced valve disease with percutaneous procedures.
And also I would like to go back to Axel Haverich’s highlight about tissue
engineering. Tissue engineering is not in competition with endovascular
valves, because you can put together the two technologies: you can implant
using percutaneous technologies tissue engineered valves. But I would be
really cautious about the experience that you mentioned right now, because
there was a nice paper in Science last week dealing with the fact that
premature papers can blast the entire field of research. So I would really be
cautious before going into the clinical field with the application of tissue
engineered valves, because we are a little bit far from that.
And finally, my last remarks, there are a few groups in Zurich and
Hannover and Boston and ourselves in Padova dealing with tissue engineered
valves, and the upscale of tissue engineered products will be a major issue,
because I don’t think—and I would like to hear from the manufacturers—I
don’t think that the manufacturers can scale up tissue engineered products,
whereas this can be, let’s say, confined to single institutions.
Mr B. Keogh (Birmingham, UK): We have an interventionist in the audience,
Dr Dawkins, and I would like to ask his view. He has heard us say that as surgeons
we should attempt to be involved in the percutaneous insertion of valves given
that we recognise that is where the future lies. The reality is that cath labs are
generally administered and financed through cardiology departments, MRI
facilities are generally in radiology departments and under the control of
radiologists. So, my question to Keith is how does he see the reality of surgeons
trying to gain access to those facilities and the funding for them.
Dr K. Dawkins (Southampton, UK): I have been sitting here listening with
interest to a very balanced view of cardiologists. The problem that was just
raised about radiologists, radiologists don’t have beds. Beds are power, and if
you don’t have beds you can’t investigate patients. The turf wars in relation to
radiology and cardiology are being lost throughout the whole world to
cardiologists. The mindset of cardiologists is more like cardiac surgeons: they
are more aggressive, they are more go-getting, and the industry is putting
millions, millions of dollars into cardiology, in all aspects, as is the
pharmaceutical industry. So the money is going to stents, is going to devices,
I am sure it is going to valve technology, but it is actually going into
cardiology, and cardiologists are grabbing this and running forward with it.
The prospects of you teaching surgeons in an operating room environment
to do procedures that cardiologists take years to train in strikes me as bizarre.
I mean, you could start doing gynecology in a cardiac operating room if there
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well developed and is currently being run by arguably the most aggressive
group in your hospital? I think it is very far-fetched to think that you will take
over that turf from cardiologists when, in many senses, the surgical budget is
being redirected to cardiology for drug-eluting stents or whatever.
So you need to refine, I think, your areas of expertise and develop them as
surgeons. You are trained as surgeons. We get called to the operating room
when people try to put an intra-aortic balloon pump in, you know, a junior
surgeon, and has destroyed the artery because they don’t know how to do these
sorts of things. And Axel, I can see, can hardly contain himself.
Mr J. Monro (Southampton, UK): Keith (Keith Dawkins), sorry, while you
still have the microphone, can I just ask how you see yourself or your
colleagues doing these percutaneous insertions of aortic valves? I seem to
remember you did some balloon valvotomies on aortic valves a few years back
in people who were perhaps at the time felt to be too old or sick for surgery,
and that didn’t last very long.
Dr Dawkins: I am going to say a few words about percutaneous valve
techniques. I think it is a niche, I really think it is a niche at the moment, but it
is an area that people are going to develop, and of course it is an area at the
extreme end, you know, the triple lutz end of interventional cardiology in
terms of manual dexterity and understanding how you move things within the
heart from minimally invasive techniques. It is the very wrong end for cardiac
surgeons to start in percutaneous techniques, in my opinion, my humble
cardiology opinion.
Dr Alfieri: We have started a kind of experiment putting a fully trained
cardiac surgeon in the cath lab to start a sort of cross training. This is going on
since a couple of months and after one week this surgeon was able to do his
first coronary angiogram and then PTCAs and so on.
In regard to percutaneous valve procedures, there are a few things which
are different from coronary interventions. First, the gatekeeper is not the
interventional cardiologist, because valve patients come from clinical
cardiologists who can refer patients directly to the surgeon. Secondly,nobody more than a cardiac surgeon knows the lesions responsible for valve
dysfunction.
In addition, the rate of complications is not low, and the problems can
only be taken care of by surgeons.
Finally, the access might require surgical preparation of the vessels.
For all these reasons, I think that surgeons should be involved in the
percutaneous procedures.
I have a question for industry people: in regard to percutaneous valve
repair/replacement techniques, are you going to involve groups with cardiac
surgeons fully involved in these programs?
Mr Guezuraga: I agree with you. The complication rates are very, very
high starting off, and industry is going to work with the cardiac surgeon in
order to be able to do the initial work, and it will go to those cardiac surgeons
who embrace this and want to do it. But at the end of the day when the
techniques are developed, whether it be repair or replacement, it will go to
the group that accepts it, and if the group that accepts it is the cardiac
surgeons because they were involved in the development and have the skill
sets, then people from my business will be selling them product on a
worldwide basis. If it goes to the cardiologists because there is a high level of
acceptance there (it is all related to risk and the amount of data that is
associated to where the state of the art is at that point in time) and the
cardiologists are willing to move forward more aggressively, then my vascular
sales force will be talking to the cardiologists.
Dr Turina: I can give you a piece of information when Andreas
Gruntzing was starting the whole business of PTCA in Zurich in 1977/1978.
I was doing the so-called surgical backup, and the incidence of
complication among the first 88 patients (the paper was published in the
Annals of Thoracic Surgery) was 11%: These patients were taken urgently
to the operating room, a part of them under continuous resuscitation. We
had a substantial number of complications, but it didn’t stop the rapid
spread of PTCA.
